Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New asthma drug shows promise in taming tough coughs

NCT ID NCT05922891

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This study tested the drug tezepelumab in 92 adults with severe asthma to see if it improves asthma control and reduces chronic cough. Participants took the drug as prescribed by their doctor, and researchers tracked their symptoms and quality of life for a year. The goal was to see how well the drug works in everyday medical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

92 people

The number who actually took part.

Started

Sep 2023

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will be a total of 90 patients with severe uncontrolled asthma who initiate new prescription of tezepelumab.

Ages

18 to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients aged ≥18 years who provide informed consent and who receive new prescription of Tezepelumab as per the physician's decision at baseline according to the package insert saying "Tezepelumab is given to patient with asthma (limited to severe or refractory patient whose asthma symptoms cannot be controlled even with existing treatment)" 2. ACQ-6 ≥1.5 at baseline 3. Patients with persistent cough ≥8 weeks up until the baseline visit according to The Japanese Respiratory Society Guidelines for the Management of Cough and Sputum 2019 Exclusion Criteria: 1. Patients who had asthma exacerbation within one month before study enrollment 2. Patients who had the biologics treatment in following period prior to the enrollment * omalizumab in 2 or 4 weeks depending on the body weight and total IgE amount * mepolizumab in 4 weeks * Benralizumab in 8 weeks * Dupilumab in 2 weeks 3. Patients with cough related diseases other than asthma as determined by treating physicians 4. Patients participating in studies that affect this study (study with other interventional treatment to evaluate efficacy/safety of treatment in patients with cough, asthma, or allergic/eosinophilic diseases) 5. Any disorder, including heart failure, malignancy, morbid obesity(BMI≧35) , respiratory infectious disease that is not stable (e.g. patients who need medical treatment) in the opinion of the investigator and could: * Affect the safety of the patient throughout the study * Impede the patient's ability to complete the entire duration of study 6. Patients with pregnancy or lactation period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma

Contacts and locations

Locations

  • Research Site

    Aomori, Japan

  • Research Site

    Bunkyō City, Japan

  • Research Site

    Fujisawa, Japan

  • Research Site

    Fukuoka, Japan

  • Research Site

    Fukushima, Japan

  • Research Site

    Hamamatsu, Japan

  • Research Site

    Hiroshima, Japan

  • Research Site

    Iizuka, Japan

  • Research Site

    Izumo, Japan

  • Research Site

    Kawasaki, Japan

  • Research Site

    Kitakyushu, Japan

  • Research Site

    Kiyose, Japan

  • Research Site

    Kurashiki, Japan

  • Research Site

    Matsusaka, Japan

  • Research Site

    Minami, Japan

  • Research Site

    Minato, Japan

  • Research Site

    Nagoya, Japan

  • Research Site

    Naka, Japan

  • Research Site

    Niigata, Japan

  • Research Site

    Nishinomiya, Japan

  • Research Site

    Osaka, Japan

  • Research Site

    Sapporo, Japan

  • Research Site

    Shinagawa City, Japan

  • Research Site

    Shinjuku, Japan

  • Research Site

    Shizuoka, Japan

  • Research Site

    tabashi City, Japan

  • Research Site

    Tennōjichō-kita, Japan

  • Research Site

    Ube, Japan

  • Research Site

    Yonago, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.